A medicinal product
intended for patients with acute myeloid leukaemia (AML) previously held a
temporary reimbursement as a Highly Innovative Medicinal Product (VILP) under
Section 39d, granted for patients with FLT3-mutated AML in first relapse,
reimbursed until disease progression, transplantation, or unacceptable
toxicity.
In a new
application, the same product was submitted for...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
